Authors
Latest:
The Pharma Marketers Guide to Medication AdherenceImproving brand adherence rates requires pharma marketers to have access to two growing bodies of knowledge. These are: 1) carefully evaluated evidence for what can improve brand revenue, and 2) informed forecasts of trends.
Latest:
Drug Innovation: Alive and Well at ASCO!This year’s annual meeting of the American Society of Clinical Oncology (ASCO), which ended on Tuesday, provided many examples of emerging therapies that offer new hope to even those patients with metastatic disease.
Latest:
The Digital World is Changing Fast. Can You Keep Up?I’ve been doing this digital thing for some time now. I’ve been part of and witnessed many changes in our digital world.
Latest:
U.S. Biosimilars Under Threat?While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the U.S. may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for biosimilars.
Latest:
My Healthcare's Better Than Your HealthcareLong before the current debate on health care started, there was a different war brewing. For decades, people have been fighting over which program and plan is best: healthcare provided to government workers, military personnel or civilians?
Latest:
Patent Filing to Drug Approval: A Difficult Journey Even for the MightyThe UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years.
Latest:
Co-Pay Offset Programs and the New Health Insurance Marketplace: Will the Feds Say No?As the health insurance marketplaces begin enrollment this week and go live on January 1, 2014, several issues continue to be a source of significant confusion to manufacturers, payers and the millions of consumers purchasing health insurance for the first time through an exchange.
Latest:
Pricing Management: It's All About the DataAny pricing or revenue management initiative is only as good as the information on which it is based.
Latest:
Talkback from Tufts: Defending R&D CostsWilliam Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.
Latest:
Why Don't Those Damn Marketers 'Do' Digital?Over the last few years I’ve worked with pharma marketers trying to preach and teach the virtues of digital channels. It has been a thankless task, with bucket loads of blood, sweat, and tears of frustration.
Latest:
World Health Assembly Underlines Pharma's Global ChallengesSusan Crowley reviews the hotly debated agenda items from last month's World Health Assembly (WHA) in Geneva, Switzerland.
Latest:
Johnson & Johnson, Sanofi Top the 2017 Good Pharma ScorecardThe 2017 GPS ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs approved by the Food and Drug Administration in 2014 that were sponsored by large drug companies.
Latest:
ESG: Applying Lessons From Consumer MarketA prime opportunity for pharma to raise its strategic game in ESG.
Latest:
Supply Chain Analytics: Pharma’s Next Big BetExamining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.
Latest:
Supply Chain Analytics: Pharma’s Next Big BetExamining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.
Latest:
Beyond the Blame Game: How Pharma is Learning to CollaborateIn a follow-up to our November CEO profile, Novo Nordisk’s Jesper Høiland writes how pharma companies and insurers are learning to collaborate.
Latest:
Marketing: Beware the Hidden Forces of Behavioral EconomicsBrand success can hinge on discovering the deeper motivations of customers and addressing the cognitive biases that result.
Latest:
FDA’s Breakthrough Therapy DesignationThree key questions dominate the agency’s Breakthrough Therapy Designation program since its 2012 launch.
Latest:
Community Clinics as Trial Sites—Bridging the Gap Between Healthcare and Clinical ResearchKeith Fern looks at how community clinics can be turned into research sites.
Latest:
Nine Pharma Lessons from the BattlefieldRick Lynch, the Army General who led the Iraqi ‘surge’ campaign, cites nine lessons that pharma leaders can apply in today’s come-from-behind struggle for market share.
Latest:
Withdrawal of EU Investigation of the Patent Box: Good News for UK InnovatorsThe European Commission’s (EC) decision to withdraw its investigation into the UK Government's Patent Box scheme is positive news for British innovators, writes Michael Jaeger.
Latest:
The End of Pharma Marketing— or a New Beginning?Two commercial marketing experts discuss how this mission critical function must change to stay relevant in bringing new therapies to the patients who need them.
Latest:
Case Study: A Drug Launch into COVID HeadwindsLessons to launch by during a pandemic—or otherwise.
Latest:
Biosimilars: Finding the Right Path to DifferentiationHow will companies market similarity in a way that differentiates from the innovator? Customer experience may be the key.
Latest:
Philanthropy vs. Innovation - Current Vaccine Prices: Is There a Downside?Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.
Latest:
Pharma Boards in the Era of Hostile TakeoversWith hostile takeovers on the rise, Mike Straw argues that pharma boards have a huge role to play in managing the people issues.
Latest:
Prastera: A Drug Listing Submission Case StudyMark Gross offers a case study in using structured product labeling (SPL) to reduce time to market.
Latest:
Pharma's Love Affair with BuzzwordsHow pharma can finally put true meaning behind its juiced-up jargon and turn the bluster into reality, by Lundbeck's Timothy White.
